^
    Back
    Association details:
    Biomarker:BOP1 overexpression
    Cancer:Triple Negative Breast Cancer
    Drug:foscenvivint (PRI724) (CBP inhibitor, β-catenin inhibitor, Wnt signalling pathway inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Pathol
    Title:

    BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated ß-catenin acetylation

    Published date:
    04/02/2021
    Excerpt:
    Notably, treating with the β-catenin/CBP inhibitor PRI-724 induced an enhancement of chemotherapeutic response of paclitaxel in BOP1-overexpressing TNBC cells.
    Secondary therapy:
    bisphosphonate bound paclitaxel
    DOI:
    10.1002/path.5676